- Home
- DAVA vs TECX Comparison
DAVA vs TECX Comparison
Compare DAVA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DAVA | TECX |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.7M | 366.8M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DAVA | TECX |
|---|---|---|
| Price | $6.76 | $19.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $16.33 | ★ $80.40 |
| AVG Volume (30 Days) | ★ 635.7K | 306.7K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.26 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,015,391,026.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | $27.07 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $6.02 | $13.70 |
| 52 Week High | $34.94 | $61.07 |
Technical Indicators
Market Signals| Indicator | DAVA | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 44.63 |
| Support Level | $6.58 | $18.97 |
| Resistance Level | $7.09 | $20.27 |
| Average True Range (ATR) | 0.28 | 1.18 |
| MACD | 0.06 | -0.23 |
| Stochastic Oscillator | 67.51 | 9.98 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About TECX Tectonic Therapeutic Inc.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.